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A B S T R A C T
Ultraconserved regions (UCRs) represent a relatively new class of non-coding genomic sequences highly con-
served between human, rat and mouse genomes. These regions can reside within exons of protein-coding genes,
despite the vast majority of them localizes within introns or intergenic regions. Several studies have undoubtedly
demonstrated that most of these regions are actively transcribed in normal cells/tissues, where they contribute to
regulate many cellular processes. Interestingly, these non-coding RNAs exhibit aberrant expression levels in
human cancer cells and their expression proﬁles have been used as prognostic factors in human malignancies, as
well as to unambiguously distinguish among distinct cancer types. In this review, we ﬁrst describe their iden-
tiﬁcation, then we provide some updated information about their genomic localization and classiﬁcation. More
importantly, we discuss about the available literature describing an overview of the mechanisms through which
some transcribed UCRs (T-UCR) contribute to cancer progression or to the metastatic spread. To date, the in-
terplay between T-UCRs and microRNAs is the most convincing evidence linking T-UCRs and tumorigenesis. The
limitations of these studies and the future challenges to be addressed in order to understand the biological role of
T-UCRs are also discussed herein. We envision that future eﬀorts are needed to convincingly include this class of
ncRNAs in the growing area of cancer therapeutics.
1. The ultraconserved regions: deﬁnition
Ultraconserved regions (UCRs), otherwise known as ultraconserved
elements (UCEs), are highly conserved sequences of human genome
that are maximally conserved with orthologous segments in rodents.
These regions have been computationally identiﬁed in 2004 by Bejerano
and colleagues as the longest segments of the human genome with the
maximal conservation rate (100% identity without indels and excluding
rRNAs) in human, mouse and rat genomes. By using this approach, the
authors could systematically deﬁne genomic segments longer than
200 bp represented in single copy in the haploid genome, widely dis-
tributed on all chromosomes except on chromosomes 21 and Y [1].
Interestingly, despite the relatively low percentage of identity between
the human and chicken genome, UCRs have extremely high levels of
conservation even in this specie. High percentage of identity was also
described in dog and fugu genomes, strongly indicating that most of
these genomic elements have undergone extreme negative selection in
many species [1]. Most of these segments do not overlap with any
coding region and the distribution of these ultraconserved genetic ele-
ments within the genome is not random. Indeed, they mostly appear in
clusters, more often than expected by chance, near coding regions for
transcription factors and molecules involved in developmental pro-
cesses. These observations have suggested the hypothesis that UCRs are
candidate regulatory elements with a relevant role in the early stages of
vertebrate development, diﬀerentiation and coordination between
cells. In addition, they are also frequently located at both fragile sites
and genomic regions involved in cancer. These functions have been
experimentally conﬁrmed for a number of elements [2,3]. Moreover,
SNPs falling within these regions are extremely under-represented (by
20-fold) across human populations, as well as in primates [4], sug-
gesting that these UCRs are under high positive selection in these
genomes. Surprisingly, the generation of transgenic mice with the
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deletion of each of the four elements contained in a large cluster of
UCE, uc.248+, uc.329+, uc.467+, and uc.482+, has no apparent
eﬀect on the phenotype [5]. Other studies have indicated that some
UCRs seem to be “phenotypically redundant” [6,7]. Therefore, it has
been hypothesized that their deletion can lead to visible phenotypes
only over many generations. These studies have clearly highlighted that
the functional conservation cannot be inferred solely from sequence
identity and vice versa [8,9].
2. UCR classiﬁcation
The ultraconserved regions of the human genome were ﬁrst classi-
ﬁed according to their genomic localisation in exonic, non-exonic and
“possibly” exonic. Later, they were re-annotated according a more re-
cent human genome assembly (i.e. hg18) and then re-classiﬁed into 5
subgroups: intergenic, intronic, exonic, partly exonic, and exon con-
taining [8]. In 2007 Calin and collaborators demonstrated, by using a
custom microarray, that a large fraction of these non-coding UCRs are
transcribed [10]. As transcriptome is routinely updated by large-scale
studies of international consortia, the genomic annotation of some T-
UCRs varied because of the presence of diﬀerent splice variants for a
given gene. Indeed, as diﬀerent isoforms may be generated from the
transcription of a given gene locus, each UCR may be labelled as
“exonic” in one transcript or “intronic” in another arising from the same
gene [11]. The UCRs are commonly deﬁned as “multiple”. Since new
updates of the human genome are released, here we provide a sche-
matic re-annotation of all 481 UCRs according to the last available
version of the human genome and of GENCODE transcriptome assembly
that, at the time of writing, are hg38 and GENCODE v26. Fig. 1 sche-
matically shows the results of this analysis. In brief, 135 and 181 UCRs
overlap with exons and introns, respectively, of annotated human
transcripts (both protein coding and not). The remaining 165 fall within
intergenic regions with variable distance from annotated gene loci,
ranging from 330 bp for the uc.335+ and LMO3 gene to ~1.4 Mb for
the uc.81+ and ACVR2A gene.
3. Transcribed-UCRs
These transcripts containing UCRs have been named transcribed
UCRs or T-UCRs, as well as ultraconserved genes (uc.) [10]. According
to the genomic orientations they can be sense (same orientation) or
antisense (opposite orientation). This pioneer paper by Calin and col-
leagues also described an important feature of T-UCRs, i.e. the high
tissue-speciﬁc expression. Indeed, they described that the highest
number of T-UCRs are expressed in B cells, while the lowest levels are
described in ovary. Noteworthy, Calin and colleagues also found that
the expression of this new class of transcribed sequences was altered in
several human cancers. In particular, by using a high throughput mi-
croarray technology they investigated the expression of T-UCRs in a
panel of 173 samples: 133 specimens were from human cancers [e.g.,
chronic lymphocytic leukaemia (CLL), colorectal (CRC), and hepato-
cellular carcinomas (HCC)] and 40 from normal tissues. They also re-
ported that T-UCRs have distinct expression signatures in human leu-
kaemia and carcinomas. The above results provided the ﬁrst link among
this class of genomic elements and cancer [11]. Following the initial
report that systematically measured T-UCRs' expression in B-cell
chronic lymphocytic leukaemia [3], other groups analysed T-UCRs le-
vels in other human malignancies. Interestingly, it has been shown that
T-UCRs expression proﬁles can be successfully used to distinguish
among diﬀerent cancer types, indicating them as new relevant tumour
biomarkers [12]. Rapid ampliﬁcation of cDNA ends (RACE) metho-
dology has been used for some T-UCRs to deﬁne the full-length tran-
scripts [10,11,13–15]. Although UCRs' genomic length ranges from 200
to 779 bp, their full-length transcriptional units usually overcome 2 kb
[10,11,13–15]. In this review, we summarize the current knowledge
about T-UCRs expression in human diseases. Improved understanding
of T-UCRs in cancer will ultimately lead to design new strategies for
prevention and/or early detection, also providing relevant information
to improve the therapeutic approaches currently available in cancer
treatment. T-UCRs are reported in literature under diﬀerent names used
by diﬀerent groups, on the basis of probe spotted on chip microarray. In
particular, in this review we will always use the abbreviation uc.
(named ‘+’) when the probes were designed according to the sense of
the genomic sequence, indeed we will use the name uc. A (“+A”) when
the probes are antisense to the genomic DNA sequence. Therefore, each
genomic UCR can have two types of transcripts, sense and antisense.
4. Associations of T-UCRs with cancer
Multiple recent reports have described that altered expression of T-
UCRs is often associated with speciﬁc tumour types. These studies have
largely highlighted a contribution of T-UCRs in carcinogenesis [16].
Table 1 summarizes the main ﬁndings on T-UCRs in diﬀerent tumours.
Among them, Braconi and colleagues, by using a genome-wide expres-
sion proﬁle analysis, identiﬁed 56 T-UCRs aberrantly expressed in
malignant HepG2 cells compared with non-malignant human hepato-
cytes. Lastly, by using in situ hybridization assay they analysed 221
HCC samples in two tissue microarrays, reporting uc.338+ as the most
up-regulated UCR in HCC compared to the normal counterpart. They
also showed that its knockdown inhibits both anchorage-dependent and
-independent cell growth, suggesting that the high levels of this T-UCR
measured in tumour samples, aﬀect the malignant phenotype [13].
Wang and collaborators have also described the same T-UCR, as the
most up regulated in CRC and CRC cell lines. They associated its ex-
pression with lymph node metastasis. Small interfering RNA (siRNA)-
mediated knockdown of uc.338+ markedly inhibited cell migration
and invasion in the microsatellite stable SW480 and in the micro-
satellite instable HCT116 CRC cell lines [17], supporting a role for this
long non-coding RNA in the metastatic process. In addition, the
uc.73+A was described in CRC as one of the most frequently up
regulated. Calin and co-workers investigated the eﬀects of uc.73+A
down regulation in COLO-320 colorectal cancer cells, using SW620
colon cancer cells—in which uc.73+A expression levels are similar to
those of normal colon cells—as a control [10]. They ﬁrst described that
the two-above-mentioned diﬀerent colon cancer cell lines, display dif-
ferent uc.73+A levels. Interestingly, its siRNA-mediated silencing
signiﬁcantly reduced COLO-320 cells' growth, whereas in SW620 cells it
did not, as these cells with very low level of this T-UCR were not ad-
dicted to its oncogenic eﬀects. Cell cycle analysis revealed an increased
fraction of COLO-320 cells in sub-G1 phase, suggesting the induction of
apoptosis in silenced cells. Annexin V and caspase 3 assays conﬁrmed
that uc.73+A knockdown was capable to induce apoptosis in cancer
cells, suggesting that high expression of this T-UCR associates with
colon cancer tumorigenesis [10]. Mestdagh and colleagues [8] found
that uc.73+ is involved in TP53 response pathway in neuroblastoma
cell line, further supporting its eﬀect on apoptosis. Sana and colla-
borators showed that the expression of both uc.73+ and uc.388+ were
down regulated in CRC (54 samples) compared to normal tissue (15
samples), suggesting their potential role as tumour-suppressors [18].
Besides uc.73+ indicated a positive correlation with overall survival,
no signiﬁcant associations of uc.73+ and uc.388+ with clinical stage,
grade, and tumour diameter were discovered. These contrasting results
with previous study [10] may be due to the diﬀerent methods used to
detect the expression of T-UCRs in CRC samples. In the former, the
authors used hybridization microarrays containing probes that detected
UCRs transcripts (in sense or antisense orientation), while in the latter
study a standard real-time PCR approach was employed, without pro-
viding strand speciﬁcity to the analysis.
More recently a gene expression proﬁling for T-UCRs has been
performed in human prostate cancer. In particular, analysing 57 tu-
mours and 7 non-cancerous prostate tissues many of the UCRs tran-
scripts were signiﬁcantly diﬀerentially expressed in tumour vs non-
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tumour tissues: the uc.106+ was found up-regulated in tumours, but
tended to be down-regulated in tumours with high Gleason grade and in
patients with extra prostatic extension of the disease (EPE) vs patients
without EPE [19]. In addition, uc.106+ knockdown in the prostate
cancer cell line LNCaP leads to the deregulation of genes involved in
proliferation and migration, indicating that uc.106+ may inﬂuence
cancer progression [19].
In 2010, Mestdagh and colleagues [8] demonstrated that T-UCRs
expression is correlated with bad prognosis and MYCN ampliﬁcation in
neuroblastoma. In particular, uc.347+, uc.350+, uc.279+, uc.460+,
uc.379+, uc.446+, and uc.364+ are over-expressed in MYCN-am-
pliﬁed (MNA) tumours compared to MYCN-non-ampliﬁed (MNN) ones,
moreover the ampliﬁcation of MYCN is associated with poor clinical
outcome in patients [8]. Accordingly, up-regulated T-UCRs were found
to be associated with several cancer-related pathways, such as those
one involved in DNA damage, cell cycle regulation, diﬀerentiation and
immune response.
The expression of T-UCRs is altered even in several hematological
malignancies. In particular, a signature of ﬁve T-UCRs, uc.269+A,
uc.160+, uc.215+, uc.346+A, and uc.348+, was able to speciﬁcally
distinguish between two main subgroups of CLL patients with diﬀerent
prognosis [10], previously classiﬁed according to the expression of 70-
kDa zeta-associated protein (ZAP-70), one of the several prognostic
markers for patients with CLL [20]. A T-UCR signature has also been
associated with histological lesions involved in the morphogenesis of
Barrett's adenocarcinoma by Fassan and collaborators through T-UCRs
microarray. Progression from normal to Barrett's oesophagus (BE) and
further to adenocarcinoma has been associated with the over-expres-
sion of uc.58+A, uc.202+A, uc.207+A, and uc.223+A and the
down-regulation of uc.214+ [21]. A 9 T-UCRs signature, described in
Table I, allowed researchers to distinguish BE from squamous epithe-
lium (Sq). This ﬁnding is particularly relevant since very little is known
about the molecular alterations occurring during the transition from
benign squamous oesophageal epithelium to metaplastic Barrett's mu-
cosa and then to neoplastic transformation. In 2013, Watters and co-
workers identiﬁed an expressional alteration in speciﬁc T-UCRs in re-
sponse to all-trans retinoic acid-induced (ATRA) diﬀerentiation in
neuroblastoma cells [22]. In particular, a gene expression microarray
analysis following knockdown of uc.300A+, revealed a number of
genes whose expression was altered by changing the lncRNA levels and
that might play a role in the increased proliferation and invasion of
neuroblastoma cells prior to all-trans-retinoic acid (ATRA)-treatment.
The authors demonstrated that the function of uc.300A+ is connected
with proliferation, invasion and the inhibition of diﬀerentiation of
neuroblastoma cell lines prior to ATRA treatment [22]. Using a custom
microarray, which was used previously to examine T-UCR expression
proﬁles in human leukaemia, colon and hepatocellular cancers
[3,10,23], Olivieri and colleagues recently identiﬁed the diﬀerential
Fig. 1. A–B. Schematic representation of the chromosomal localization of the 481-ultraconserved regions (UCRs) on ideograms of the 24 human chromosomes. UCRs genomic coordinates
were ﬁrst mapped on the latest release of the human genome (hg38) and then intersected with human transcriptome (GENCODE v26 release) using BedTools. Data were plotted along
chromosomal ideograms using IdeoViz package in R language. Exon-overlapping UCRs are reported as red marks extending above the chromosome with the corresponding oﬃcial gene
symbol; intronic elements are reported as blue marks below the chromosome; intergenic UCRs as green marks above the chromosomes. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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expression of T-UCRs in malignant and non-malignant urothelial tissues
[11]. In particular, they investigate the functional characterization of
uc.8+ as the most up regulated T-UCR in bladder cancer tissues. In
vitro experiments showed signiﬁcant decreased capacities for bladder
cancer cell invasion, migration, and proliferation, following uc.8+
knockdown.
5. Genetic variants in ultraconserved regions associate with
cancer
Bejerano and co-workers reported that only six single-nucleotide
polymorphisms (SNPs) in a total of 481 UCRs were validated in NCBI's
SNP database (dbSNP) of human genome [1]. These six SNPs are lo-
cated in the region of uc.53+, uc.140+, uc.252+, uc.295+,
uc.353+ and uc.374+, respectively. The evolutionary analysis by
Katzman and collaborators further demonstrated that ultraconserved
regions are under a stronger selection compared to protein-coding
genes, suggesting that these DNA portions are selectively constrained
and contain functional variation [24]. In addition, Drake and colleagues
measured in these positions the allele frequency distributions in the
human population describing that these are rarer than new alleles in
non-conserved regions [12]. Furthermore, Silla and colleagues identi-
ﬁed that prevalent variants in UCR sequences are less likely to overlap
transcription factor binding site, meaning that allele frequencies of
variants identify selective pressure on transcription factor binding [25].
In 2010, Wojcik and collaborators demonstrated that germline mu-
tations, as well as single nucleotide polymorphisms (SNPs) in UCR,
occur more frequently in patients with colon cancer and chronic leu-
kaemia than in the general population [26]. Thus, these SNPs could be
excellent predictors of individual risk of cancer, treatment eﬃcacy, and
prognosis. Several studies have investigated the association between
genetic polymorphisms within UCRs and cancer risk. In particular Yang
and colleagues [27], by studying the potential impact of the six under-
represented SNPs identiﬁed by Bejerano and collaborators [1] within
UCRs, have reported that two of them (rs9572903 and rs2056116) are
associated with familial breast cancer (BC) risk by comparing 1214
German patients negative for BRCA1 and BRCA2 genes' mutations and
2084 German female blood donors. Conversely, Shen and collaborators
Table 1
Main ﬁndings on T-UCRs in diﬀerent tumours. a
T-UCR 
name
Genomic 
localization
Cancer 
type
T-UCR 
expression Biological or molecular function in cancer Reference
uc.8+ Chr.1p36.22 BlCa Up regulated
KD inhibits cell migration, invasion and 
proliferation in J82 cell line, promoting bladder 
cancer tumorigenesis
11
uc.73+ Chr.2q22.3 CRC Down regulated Associated with poor survival of CRC patients 18
uc.73+ Chr.2q22.3 NB Up regulated TP53 response pathway: apoptotic effect 8
uc.73+A Chr.2q22.3 CRC Up regulated KD in COLO-320 cell line, increases sub-G1phase cells, indicating a role in apoptosis 10
uc.106+ Chr.2q31.1 PCa Up regulated KD leads to a down regulation of genes involved in proliferation and migration 19
uc.300+A Chr.10q24.31 NB Up regulated
Involved in the proliferation, invasion and 
inhibition of differentiation of neuroblastoma cell 
lines prior to ATRA treatment.
22
uc.338+ Chr.12q13.13 HCC Up regulated KD reduces anchorage dependent and independent growth oh HCC cells 13
uc.338+ Chr.12q13.13 CRC Up regulated
KD inhibits cell migration and invasion in 
SW480 and HCT116 cell lines, promoting 
invasion and metastasis
17
uc.388+ Chr.15q21.3 CRC Down regulated Associated with distal location of CRC 18
uc.460+ Chr.Xp22.11 NB Up regulated Activated by amplified MYCN in tumours 8
uc.269+A
uc.160+
uc.215+
uc.346+A
uc.348+
Chr.9q33.3
CLL Up regulated CLL prognosis 20
Chr.5q14.1
Chr.7p14.1
Chr.12q23.3
Chr.13q21.33
uc.58+A
uc.202+A
uc.207+A
uc.223+A
uc.214+
Chr.2p16.1
Barrett's 
adenocarcin
oma
Up regulated Progression from normal to Barrett's oesophagus
21
Chr.6q16.3
Chr.7p15.3
Chr.7q31.1
Chr.7p14.3 Down regulated KD leads to Barrett's oesophagus carcinogenesis
uc.161+A
uc.165+A
uc.327+A
uc.153+A
uc.158+A
uc.206+A
uc.274+A
uc.472+A
uc.473+A
Chr.5q14.1
Down regulated
Progression from squamous oesophagus to 
Barrett's oesophagus carcinogenesis
Chr.5q14.3
Chr.11p13
Chr.5q13.2
Up regulated
Chr.5q14.1
Chr.7p15.3
Chr.9q33.3
Chr.Xp11.4
Chr.Xq13.1
uc.347+
uc.350+
uc.279+
uc.460+
uc.379+
uc.446+
uc.364+
Chr.13q21.33
NB Up regulated Involved in in MYCN-amplified (MNA) tumours 20
Chr.13q21.33
Chr.9q33.3
Chr.Xp22.11
Chr.14q32.2
Chr.19q12
Chr.14q12
ATRA – all trans-retinoic acid; KD – knock down; BlCa – bladder cancer; CRC – colorectal carcinoma; NB – neuroblastoma; PCa – prostate
cancer; HCC – hepatocellular carcinoma; CLL – chronic lymphocytic leukaemia.
a A+ means the transcription is in antisense with the genomic orientation (telomere to centromer for the short arm of chromosomes and
centromere to telomere, for the long arm of chromosomes).
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[28] failed to support any signiﬁcant association of the six identiﬁed
SNPs including rs9572903 and rs2056116 with BC risk in Chinese po-
pulation. Catucci and collaborators [29] did not ﬁnd any signiﬁcant
association between these two SNPs and familial BC risk in Italian po-
pulation without mutations in BRCA1/2 genes. As the authors suggest
in their manuscript, these conﬂicting results rely on diﬀerences in allele
frequency of diﬀerent populations. However, in another study carried
out on patients with locally advanced colorectal adenocarcinoma
treated with adjuvant ﬂuoropyrimidine-based chemotherapy, the au-
thors selected 48 potentially functional SNPs within UCEs and sys-
tematically evaluated their individual and joint associations with clin-
ical outcomes [29]. Only for stage II patients with at least one variant
allele of rs7849, consistent association with increased recurrence risk
was observed in the training validation, and meta-analysis set [29].
Recently, another study reported that the SNPs rs8004379 con-
tained in the uc.368+ was signiﬁcantly associated with biochemical
recurrence in two independent cohorts of localized prostate cancer
patients (PCa) [28]. A consistent association of the same SNP with a
decreased risk for prostate cancer-speciﬁc mortality was also observed.
Bao and collaborators systematically evaluated 14 common SNPs
within UCRs in three cohorts of PCa patients, to test the hypothesis that
these UCR SNPs might inﬂuence clinical outcomes. Multivariate ana-
lysis adjusting for known clinical parameters found an association be-
tween rs8004379 and recurrence in localized disease. Remarkably, a
consistent association of rs8004379 with a decreased risk for prostate
cancer-speciﬁc mortality was also observed in the advanced PCa patient
group. Their ﬁnding suggests that SNPs within UCRs may be valuable
prognostic biomarkers for assessing PCa treatment response and sur-
vival [30]. In Table 2 we summarize the main ﬁndings on SNPs located
in several T-UCRs in diﬀerent tumours. As increasing number of studies
on T-UCRs are going to be published, it is reasonable to speculate that
even more details about the speciﬁc roles of T-UCR in cancer will be
demonstrated soon.
6. Regulation of T-UCRs by direct interaction with microRNAs
To date, experimental evidence supports that the aberrant regula-
tion of T-UCRs expression in cancer is driven by two main mechanisms:
the altered interaction with regulatory non-coding RNA, such as
miRNAs, and the hypermethylation of CpG island located in T-UCR
promoters.
In 2007 Calin and colleagues gave the ﬁrst evidence that T-UCRs are
functional miRNA targets [11]. They demonstrated that some T-UCRs
are directly regulated by highly expressed microRNAs via base pairing
in CLL cells. In particular, uc.160+, uc.346+A and uc.348+ showed
signiﬁcant antisense complementarity with miR-24-1 miR-155, miR-
146, miR-29b respectively. A negative expression correlation has been
reported for each T-UCR with the corresponding microRNA levels in
CLL samples. Furthermore, uc.348+, uc.346+A and uc.160+ were
cloned into luciferase reporter vectors to conﬁrm their interaction with
miR-155, miR-24-1 and miR-29-b in vitro [11]. Each T-UCR::microRNA
interaction was extensively validated by measuring the expression le-
vels of uc.160+ and uc.346+A after the overexpression of miR-155 in
leukaemia cells. In addition, uc.160+ and uc.346+A were down
regulated after miR-155 transfection in human megakaryoblastic leu-
kaemia cell line MEG-01 [11]. Similarly, Scaruﬃ and colleagues found a
negative correlation between expression values of nine speciﬁc T-UCRs
(uc.209+, uc.271+, uc.312+, uc.330+, uc.371+, uc.411+,
uc.421+, uc.435+, uc.452+) and ﬁve miRNAs, which allow distin-
guishing between long- and short-surviving high-risk neuroblastoma
(NB) patients [31]. In 2016, Goto and colleagues found an over-
expression of uc.416+A in gastric cancer (GC) biopsies and identiﬁed a
miR-153 binding site in the uc.416+A RNA transcript. Modulation of
miR-153 changed uc.416+A expression in GC cells line MKN-74,
suggesting a direct regulation of uc.416+A expression by miR-153
[32]. In all these studies, the authors focused on the high sequence
complementarity between the two non-coding RNA species, indicated
by the huge number of miRNA::T-UCR interacting pairs. Most im-
portantly, these ﬁndings suggest that both RNA species are involved in,
and cooperate to, initiating or sustaining human tumorigenesis.
7. Regulation of microRNAs processing by direct interaction with
T-UCRs
Sequestering of miRNA by endogenous RNAs (both coding and
noncoding) has been only recently demonstrated in plants [33] and
mammals [5,34]. Interestingly, the ﬁrst report describing a direct reg-
ulation of miRNAs by an endogenous ultraconserved RNA was in HCT-
116 human colorectal cancer cells by Liz and co-workers in 2014 [9].
Authors reported that the uc.283+A directly binds the pri-miR-195.
The complementarity involved 11 nucleotides situated immediately
upstream of the Drosha cropping site within the miR-195 primary
transcript. As validated in vivo and in vitro, the overexpression of
uc.283+A in HCT-116 colorectal cancer cells impair the proper pro-
cessing of miR-195. Carotenuto and co-workers provided the ﬁrst evi-
dence that uc.158+A is dependent by the Wnt pathway activation in
liver cancer and drives its growth [15]. In particular, they demonstrated
that inhibition of uc.158+A reduced cell growth, and spheroid-based
cell migration, and increased apoptosis in human malignant hepato-
cytes cells line HepG2 and SW1 [15]. miR-193b was predicted to have
binding sites within the uc.158+A conserved sequence. Experimental
modulation of uc.158+A aﬀected miR-193b expression in human
malignant hepatocytes supporting its role as a competing endogenous
long non-coding RNAs. In addition, co-transfection of uc.158+A in-
hibitor and anti-miR-193b rescued the eﬀect of uc.158+A inhibition
on cell viability. More recently, it was demonstrated that the uc.8+, up
regulated in bladder cancer, is able to interact with miR-596, and that it
is involved in the promotion and development of BlCa. By using in vitro
Table 2
SNPs contained in T-UCRs in diﬀerent tumours.
T-UCR 
name
Genomic Localization Single Nucleotide Polymorphism (SNP) Cancer type Reference
uc.53+
uc.140+
uc.252+
uc.295+
uc.353+
uc.374+
Chr.2p16.1
Chr.4p15.33
Chr.9p22.2
Chr.10q24.31
Chr.13q21.33
Chr.14q13.3
rs1861100
rs2056116
rs1538101
rs7092999
rs9572903
rs7143938
None 1
uc.140+
uc.353+
Chr.4p15.33
Chr.13q21.33
rs2056116
rs9572903 BC in German Population 27
uc.140+
uc.353+
Chr.4p15.33
Chr.13q21.33
rs2056116
rs9572903 BC in Chinese Population 28
uc.140+
uc.353+
Chr.4p15.33
Chr.13q21.33
rs2056116
rs9572903 BC in Italian Population 29
uc.368+ Chr.14q13.1 rs8004379 PCa 28, 30
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validation, uc.8+ was shown to be a natural decoy for miR-596 [10].
In addition, we found that the polycomb protein Yin Yang 1 (YY1)
mediates the binding between miR-596 and T-UCR 8+ [35]. Thus,
uc.8+ up regulation results in increased expression of MMP9 that in-
creases the invasive potential of BlCa cells. Moreover, uc.8+ silencing
increased miR-596 expression, which in turn reduced total uc.283+
[34]. These results show that the perturbation of one element in this
network (speciﬁcally the T-UCR) is able to modify also the expression of
other interactors (such as miRNAs). Thus, this potentially represents a
new regulatory layer in which this new class of lncRNA modulate
miRNAs levels. This new function opens up new scenarios for the un-
derstanding of how the interaction among diﬀerent non-coding RNA
molecules can regulate gene expression in physiologic processes and as
its alteration is linked to pathophysiology [35].
8. T-UCR and epigenetic modiﬁcation
As occurs with protein coding genes and miRNAs, hypermethylation
of CpGs also regulate the expression of lncRNA and in particular T-
UCRs. The presence of a canonical CpG island within a 2000-bp dis-
tance upstream the sense transcript of uc.160+, uc.283+A, and
uc.346+ was found by Lujambio and colleagues [14]. In particular, a
hypermethylation of a CpG island and the following transcriptional
silencing was demonstrated in HCT-116 colorectal cancer cells and in
other cell lines, such as breast (MCF-7, MDA-MB-231, CAMA-1), lung
(H552, H441, H358, EBC1), lymphoma (Ramos, Raji, Namalwa), and
leukaemia cells (HL-60, Jurkat, KG-1a). In addition, also in diﬀerent
human primary malignancies the authors observed the hypermethyla-
tion of CpGs nearby uc.160+, uc.283+A and uc.346+ in primary
colon, breast and lung tumours, in melanomas, leukaemia and lym-
phomas [36]. This reinforced the link between CpG islands' hy-
permethylation and T-UCRs silencing.
Hudson and co-workers have recently reported that the treatment of
LNCaP (prostate cancer cell line) with 5-AzaC—a chemical analogue of
cytidine capable to inhibit DNA methyltransferases and to induce DNA
hypomethylation—increases the expression of six T-UCRs, uc.308+A,
uc.434+A, uc.241+A, uc.283+A, uc.285+, uc.85+ [19]. Among
them, the uc.283+A has been previously reported to undergo tran-
scriptional silencing through CpG hypermethylation [37]. These results
also indicated that these T-UCRs are epigenetically silenced also in
prostate cancer. Mestdagh and colleagues [8] evaluated the distance
distribution of trimethylation of lysine 4 of histone H3 (H3K4me3)—a
marker of transcription initiation—of intergenic and intragenic T-UCRs
in four diﬀerent cell lines. This study has reported that intergenic and
intragenic T-UCRs signiﬁcantly associate with active H3K4me3, but
they noted a diﬀerent distribution compared to protein-coding genes.
Conversely, they observed H3K4me3 marks' distribution similar to
miRNAs, suggesting common features in the transcriptional organiza-
tion for these two classes of ncRNAs [8].
In 2016, Goto and colleagues, found down regulation of uc.158+A
expression in GC as well as PCa. The expression was consistently re-
stored after 5-Aza-dC (5-aza-2′-deoxycytidine) treatment in four cell
lines. Bisulﬁte genomic sequencing revealed a cancer-speciﬁc CpG hy-
permethylation upstream of uc.158+A in LNCaP and DU145 cells as
well as both in PCa and GC biopsies [31].
Taken together, a large body of evidence indicates that, similarly to
miRNAs, also T-UCRs are susceptible to DNA methylation-associated
inactivation in transformed cells, supporting the model in which ge-
netic and epigenetic alterations in both coding and noncoding se-
quences cooperate in human tumorigenesis. Furthermore, given the
recent discoveries about the eﬀects of distant regulatory regions—such
as enhancers [38] and super-enhancers [39]—on the activation of long
non-coding RNAs in tumours, it is reasonable to speculate that also T-
UCRs may undergo a similar epigenetic regulatory mechanism. Further
studies in this direction are needed in the next future.
9. Perspectives and concluding remarks
Since their discovery, establishing the functional role of the ultra-
conserved transcribed elements of the human genome has been chal-
lenging. Most of our knowledge about UCEs mainly derives from
computational analysis and thus from informatics predictions. To date,
active transcription arising from most of these regions has not been
experimentally conﬁrmed nor it has been linked to speciﬁc biological
processes. In many cases, the full-length sequence of these transcripts
has not been determined yet. In addition, it has not been fully estab-
lished the origin of these patterns with a high conservation across the
species. Despite several studies have clearly linked the expression of T-
UCRs to human diseases, and particularly to cancer, it has not been well
established if their alteration has a causal or secondary role in cancer
onset/progression. Therefore, a wide and robust body of experimental
evidences is needed to ascertain their possible pathogenic contribution
in cancer. However, a systematic characterization of T-UCRs in each
tissue and their peculiar expression in speciﬁc cancer could be in-
formative also to integrate—and to make more speciﬁc and sensiti-
ve—currently available cancer panels, widely used for prognostic and
diagnostic purposes.
Indeed, it is now widely assumed that the expression of well-studies
classes of non-coding RNAs (miRNAs and lncRNAs, including also the
primary transcripts of microRNAs, that are less studied these days)
[40–41] associates with patients' prognosis in many cancer types.
Cancer panels including even T-UCRs signatures can be used in proof-
of-principle to predict prognosis or other clinical outcomes (such as the
response to therapy). We therefore envisage that T-UCRs-based prog-
nostic/diagnostic kits will be released on the market, with the speciﬁc
aim to help clinicians in a better, and more accurate, characterization of
the histological subtype of cancer. However, their potential therapeutic
use is still far, due to a substantial lack about their biological role in
many contexts [42]. Since the knowledge of T-UCRs is still in its in-
fancy—especially if compared to other ncRNAs classes—further studies
are needed to convincingly include these ncRNAs in the growing area of
cancer therapeutics.
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